Entrada receives authorization to start exon 44 skipping trial in Europe

- Posted in General, Research
Entrada Europe

CureDuchenne provided early funding to Entrada Therapeutics.  Entrada has received regulatory authorization in Europe to initiate a Phase 1/2 clinical trial of ENTR-601-44 in ambulatory individuals with Duchenne amenable to skipping exon 44.  The study, which will run in the UK and the EU, will start in the 2nd quarter of 2025.  Entrada is also planning a Phase 1/2 for ambulatory individuals with Duchenne amenable to skipping exon 45, which will start in the UK in the 3rd quarter of 2025. 

Read the press release HERE:  https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-reports-first-quarter-2025-financial

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate